Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience
- Published on 05/05/2026
- Reading time: 5 min.
Su Malcolm 1, Yates Sean 2, Sanchez Melissa 3, Shen Yu-Min 4
1 https://ror.org/05byvp690 Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA
2 https://ror.org/05byvp690 Division of Transfusion Medicine and Hemostasis, Department of Pathology University of Texas Southwestern Medical Center Dallas TX USA
3 https://ror.org/04rt7ps04 Department of Pathology Parkland Health and Hospital System Dallas TX USA
4 https://ror.org/05byvp690 Division of Hematology and Oncology, Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA
Abstract
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of AHA patients treated with emicizumab in an academic center between January 2020 and June 2024. There were 5 male and 7 female patients, with median (interquartile range [IQR]) age and maximum inhibitor titer of 73 (60–76)...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Hematology
Receive our newsletter to stay up to date with the latest news in Hematology
